Xue Bo Zeng
Direktor/Vorstandsmitglied bei SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Profil
Xue Bo Zeng is currently the Director at Chiral Quest (Suzhou) Co., Ltd., Director at Shanghai Model Organisms Center, Inc., Director at Hangzhou Sciwind Biosciences Co., Ltd., Non-Executive Director at Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Executive Director at IDG Capital, Director at Shandong Bestcomm Pharmaceutical Co., Ltd., Independent Director at CASI Pharmaceuticals, Inc., and Vice President at Hexie Zhuorui Zhuhai Investment Management Co. Ltd.
Mr. Zeng previously worked as Deputy Director at Shenzhen Investment Holdings Co., Ltd.
Mr. Zeng obtained an undergraduate degree from Qinghai Nationalities University in 2009.
Aktive Positionen von Xue Bo Zeng
Unternehmen | Position | Beginn |
---|---|---|
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Direktor/Vorstandsmitglied | 30.07.2022 |
CASI PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 21.03.2023 |
SHANGHAI MODEL ORGANISMS CENTER, INC. | Direktor/Vorstandsmitglied | 01.09.2022 |
IDG Capital | Direktor/Vorstandsmitglied | 01.01.2016 |
Hexie Zhuorui Zhuhai Investment Management Co. Ltd. | Corporate Officer/Principal | 01.11.2020 |
Shandong Bestcomm Pharmaceutical Co., Ltd.
Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China. | Direktor/Vorstandsmitglied | 01.12.2017 |
Hangzhou Sciwind Biosciences Co., Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Direktor/Vorstandsmitglied | - |
Chiral Quest (Suzhou) Co., Ltd.
Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Xue Bo Zeng
Unternehmen | Position | Ende |
---|---|---|
Shenzhen Investment Holdings Co., Ltd.
Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Corporate Officer/Principal | 01.07.2016 |
Ausbildung von Xue Bo Zeng
Qinghai Nationalities University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Health Technology |
CASI PHARMACEUTICALS, INC. | Health Technology |
SHANGHAI MODEL ORGANISMS CENTER, INC. | Commercial Services |
Private Unternehmen | 6 |
---|---|
IDG Capital | |
Shenzhen Investment Holdings Co., Ltd.
Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Finance |
Hexie Zhuorui Zhuhai Investment Management Co. Ltd. | |
Shandong Bestcomm Pharmaceutical Co., Ltd.
Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China. | Commercial Services |
Hangzhou Sciwind Biosciences Co., Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Health Technology |
Chiral Quest (Suzhou) Co., Ltd.
Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Commercial Services |